Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Prostate cancer in 2013

The changing role of imaging in clinical care

Considerable developments in prostate cancer in 2013 have emerged from the imaging field. Hyperpolarized 13C-MRI can monitor metabolic activity to identify high-grade disease and treatment response, and novel PET radiotracers might identify distinct subsets of patients with advanced disease. These examples highlight the progress made at all stages of care.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

References

  1. Puech, P. et al. Prostate cancer diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy--prospective multicenter study. Radiology 268, 461–469 (2013).

    Article  Google Scholar 

  2. Cooperberg, M. R. et al. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J. Clin. Oncol. 31, 1428–1434 (2013).

    Article  CAS  Google Scholar 

  3. Turkbey, B. et al. Prostate cancer: can multiparametric MR imaging help identify patients who are candidates for active surveillance? Radiology 268, 144–152 (2013).

    Article  Google Scholar 

  4. Nelson, S. J. et al. Metabolic imaging of patients with prostate cancer using hyperpolarized [1-13C]pyruvate. Sci. Transl. Med. 5, 198ra108 (2013).

    Article  Google Scholar 

  5. Evangelista, L. et al. Choline PET or PET/CT and biochemical relapse of prostate cancer: a systematic review and meta-analysis. Clin. Nucl. Med. 38, 305–314 (2013).

    Article  Google Scholar 

  6. Beheshti, M., Langsteger, W. & Fogelman, I. Prostate cancer: role of SPECT and PET in imaging bone metastases. Semin. Nucl Med. 39, 396–407 (2009).

    Article  Google Scholar 

  7. Mosquera, J. M. et al. Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia 15, 1–10 (2013).

    Article  CAS  Google Scholar 

  8. Jadvar, H. Molecular imaging of prostate cancer with PET. J. Nucl. Med. 54, 1685–1688 (2013).

    Article  CAS  Google Scholar 

  9. Osborne, J. R. et al. A prospective pilot study of 89Zr-J591/PSMA positron emission tomography (PET) in men with localized prostate cancer undergoing radical prostatectomy. J. Urol. http://dx.doi.org/10.1016/j.juro.2013.10.041.

  10. Walia, G., Pienta, K. J., Simons, J. W. & Soule, H. R. The 19th annual Prostate Cancer Foundation scientific retreat. Cancer Res. 73, 4988–4991 (2013).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to John Kurhanewicz.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Aggarwal, R., Kurhanewicz, J. The changing role of imaging in clinical care. Nat Rev Urol 11, 75–77 (2014). https://doi.org/10.1038/nrurol.2013.319

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2013.319

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing